The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): Final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: The ROSORC trial.
Elena Verzoni
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Sergio Bracarda
No relevant relationships to disclose
Sergio Ricci
No relevant relationships to disclose
Cosimo Sacco
No relevant relationships to disclose
Laura Ridolfi
No relevant relationships to disclose
Camillo Porta
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; Novartis
Rosalba Miceli
No relevant relationships to disclose
Nicoletta Zilembo
No relevant relationships to disclose
Emilio Bajetta
No relevant relationships to disclose
Giuseppe Procopio
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline
Honoraria - Novartis; Pfizer